Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics

The anti-CD20 antibody rituximab (RTX; Rituxan®, MabThera®) was the first anti-cancer antibody approved by the US Food and Drug Administration in 1997 and it is now the most-studied unconjugated therapeutic antibody. The knowledge gained over the past 15 y on the pharmacodynamics (PD) of this antibo...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Golay, Josée, Semenzato, Gianpietro, Rambaldi, Alessandro, Foà, Robin, Gaidano, Gianluca, Gamba, Enrica, Pane, Fabrizio, Pinto, Antonello, Specchia, Giorgina, Zaja, Francesco, Regazzi, Mario
Format: Artigo
Jezik:Inglês
Izdano: Landes Bioscience 2013
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3896596/
https://ncbi.nlm.nih.gov/pubmed/23933992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.26008
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki